Lung cancer (Amsterdam, Netherlands), 2016-12, Vol.102, p.65-73
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
- Ist Teil von
- Lung cancer (Amsterdam, Netherlands), 2016-12, Vol.102, p.65-73
- Ort / Verlag
- Ireland: Elsevier Ireland Ltd
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • Nintedanib plus docetaxel improved PFS for pretreated NSCLC compared with docetaxel in LUME-Lung 1. • LUME-Lung 2 investigated nintedanib plus pemetrexed in pretreated non-squamous NSCLC. • The trial was stopped early although did meet the primary endpoint (PFS). • There were no safety concerns with the addition of nintedanib to pemetrexed.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0169-5002eISSN: 1872-8332DOI: 10.1016/j.lungcan.2016.10.011Titel-ID: cdi_proquest_miscellaneous_1851299970
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Angiogenesis inhibitor, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - pathology, Disease-Free Survival, Double-Blind Method, Enzyme Inhibitors - administration & dosage, Female, Hematology, Oncology and Palliative Medicine, Humans, Indoles - administration & dosage, Indoles - adverse effects, Lung Neoplasms - drug therapy, Lung Neoplasms - pathology, Male, Middle Aged, Neoplasm Staging, Nintedanib, Non-small cell lung cancer, Pemetrexed - administration & dosage, Pemetrexed - adverse effects, Pemetrexed - therapeutic use, Phase III, Placebos, Pulmonary/Respiratory, Second-line, Treatment Outcome